A labile point in mutant amphotericin polyketide synthasesKHAN, Naseem; RAWLINGS, Bernard; CAFFREY, Patrick et al.Biotechnology letters. 2011, Vol 33, Num 6, pp 1121-1126, issn 0141-5492, 6 p.Article

Amphotericin BLEMKE, A; KIDERLEN, A. F; KAYSER, O et al.Applied microbiology and biotechnology. 2005, Vol 68, Num 2, pp 151-162, issn 0175-7598, 12 p.Article

STABILITY STUDIES WITH AMPHOTERICIN B AND AMPHOTERICIN B METHYL ESTERBONNER DP; MECHLINSKI W; SCHAFFNER CP et al.1975; J. ANTIBIOT.; JAP.; DA. 1975; VOL. 28; NO 2; PP. 132-135; BIBL. 10REF.Article

Lipid formulations of amphotericin B as first-line treatment of zygomycosisPETRIKKOS, G. L.Clinical microbiology and infection. Supplement. 2009, Vol 15, Num 5, pp 87-92, issn 1470-9465, 6 p.Conference Paper

COMPARATIVE IN VITRO ANTIFUNGAL ACTIVITY OF AMPHOTERICINB AND AMPHOTERICIN B METHYL ESTERHOWARTH WR; TEWARI RP; SOLOTOROVSKY M et al.1975; ANTIMICROB. AGENTS CHEMOTHERAPY; U.S.A.; DA. 1975; VOL. 7; NO 1; PP. 58-63; BIBL. 11REF.Article

Large-conductance cholesterol-amphotericin B channels in reconstituted lipid bilayersYILMA, Solomon; CANNON-SYKORA, Jennifer; SAMOYLOV, Alexandre et al.Biosensors & bioelectronics. 2007, Vol 22, Num 7, pp 1359-1367, issn 0956-5663, 9 p.Article

Acute amphotericin B overdoseBURKE, Douglas; LAL, Rajiv; FINKEL, Kevin W et al.The Annals of pharmacotherapy. 2006, Vol 40, Num 12, pp 2254-2259, issn 1060-0280, 6 p.Article

REDUCED TOXICITY OF AMPHOTERICIN B METHYL ESTER (AME)VS. AMPHOTERICIN B AND FUNGIZONE IN TISSUE CULTURE = REDUCTION DE LA TOXICITE DE L'ESTER METHYLIQUE D'AMPHOTERICINE B(EMA) PAR RAPPORT A L'AMPHOTERICINE B ET LA FUNGIZONE EN CULTURE DE TISSUFISHER PB; GOLDSTEIN NI; BRYSON V et al.1976; IN VITRO; U.S.A.; DA. 1976; VOL. 12; NO 2; PP. 133-140; BIBL. 1 P. 1/2Article

Peptide stabilized amphotericin B nanodisksTUFTELAND, Megan; PESAVENTO, Joseph B; BERMINGHAM, Rachelle L et al.Peptides (New York, NY. 1980). 2007, Vol 28, Num 4, pp 741-746, issn 0196-9781, 6 p.Article

Liposomal amphotericin B. Author's repliesRINGDEN, O; TOLLEMAR, J; TYDEN, G et al.Lancet (British edition). 1992, Vol 339, Num 8789, pp 374-375, issn 0140-6736Article

Possible liposomal amphotericin B-induced nephrogenic diabetes insipidusCANADA, Todd W; WEAVIND, Lisa M; AUGUSTIN, Kristan M et al.The Annals of pharmacotherapy. 2003, Vol 37, Num 1, pp 70-73, issn 1060-0280, 4 p.Article

Antifungals and renal safety- : getting the balance rightSALIBA, Faouzi.International journal of antimicrobial agents. 2006, Vol 27, issn 0924-8579, S21-S24, SUP1Article

Interactions between amphotericin B 3-(N',N'-dimethylamino) propyl amide and cellular membrane components in Langmuir monolayersHAC-WYDRO, Katarzyna; DYNAROWICZ-LATKA, Patrycja; GRZYBOWSKA, Jolanta et al.Thin solid films. 2008, Vol 516, Num 6, pp 1197-1203, issn 0040-6090, 7 p.Article

Current Options in Antifungal PharmacotherapyMOHR, John; JOHNSON, Melissa; COOPER, Travis et al.Pharmacotherapy. 2008, Vol 28, Num 5, pp 614-645, issn 0277-0008, 32 p.Article

Evaluation of the post-antifungal effect (PAFE) of amphotericin B and nystatin against 30 zygomycetes using two different mediaVITALE, Roxana G; MEIS, Jacques F. G. M; MOUTON, Johan W et al.Journal of antimicrobial chemotherapy (Print). 2003, Vol 52, Num 1, pp 65-70, issn 0305-7453, 6 p.Article

Interactions between amphotericin B and sterols in monolayers. Mixed films of amphotericin B-cholesterolSEOANE, R; MINONES, J; CONDE, O et al.Langmuir. 1999, Vol 15, Num 17, pp 5567-5573, issn 0743-7463Article

A BIOLOGICALLY ACTIVE BORATE DERIVATIVE OF AMPHOTERICIN B SOLUBLE IN SALINE SOLUTION.KRAL F; STRAUSS G.1978; J. ANTIBIOT.; JAP.; DA. 1978; VOL. 31; NO 2; PP. 257-259; BIBL. 6 REF.Article

COMPARATIVE CHEMOTHERAPEUTIC ACTIVITY OF AMPHOTERICIN B AND AMPHOTERICIN B METHYL ESTERBONNER DP; TEWARI RP; SOLOTOROVSKY M et al.1975; ANTIMICROB. AGENTS CHEMOTHERAPY; U.S.A.; DA. 1975; VOL. 7; NO 6; PP. 724-729; BIBL. 14REF.Article

Fusariose cutanée atypique chez un sujet immunocompétent = Atypical cutaneous Fusarium infection in an immunocompetent patientZRIBI, J; BOUDAYA, S; SALLEMI, A et al.Annales de dermatologie et de vénéréologie. 2010, Vol 137, Num 10, pp 630-634, issn 0151-9638, 5 p.Article

Comparison of in vitro antifungal activities of amphotericin B lipid complex with itraconazole against 708 Clinical yeast isolates and opportunistic moulds determined by National Committee for Clinical Laboratory Standards Methods M27-A and M38-PCARRILLO-MUNOZ, Alfonso Javier; RUESGA, Maite; QUINDOS, Guillermo et al.Chemotherapy (Basel). 2002, Vol 48, Num 5, pp 224-231, issn 0009-3157, 8 p.Article

Role of phospholipid transfer protein on the plasma distribution of amphotericin B following the incubation of different amphotericin B formulationsPATANKAR, Nilesh; WASAN, Kishor M.Pharmaceutical research. 2006, Vol 23, Num 5, pp 1020-1024, issn 0724-8741, 5 p.Article

Use of liposomal amphotericin B in the treatment of disseminated coccidioidomycosisANTONY, Suresh; DOMINGUEZ, Delfina C; SOTELO, Elsa et al.Journal of the National Medical Association. 2003, Vol 95, Num 10, pp 982-985, issn 0027-9684, 4 p.Article

Nephrotoxicity Associated With Amphotericin B Deoxycholate in NeonatesLE, Jennifer; ADLER-SHOHET, Felice C; NGUYEN, Christine et al.The Pediatric infectious disease journal. 2009, Vol 28, Num 12, pp 1061-1063, issn 0891-3668, 3 p.Article

What is the current and future status of conventional amphotericin B?KLEINBERG, Michael.International journal of antimicrobial agents. 2006, Vol 27, issn 0924-8579, S12-S16, SUP1Article

Pharmacodynamics and Pharmacokinetics of Antifungals for Treatment of Invasive AspergillosisBELLMANN, Romuald.Current pharmaceutical design (Print). 2013, Vol 19, Num 20, pp 3629-3647, issn 1381-6128, 19 p.Article